Description

Pasireotide acetate is a long-acting cyclic hexapeptide designed to inhibit hormone secretion by targeting multiple somatostatin receptors—particularly SST1, SST2, SST3, and SST5. It effectively suppresses growth hormone (GH), IGF-I, and ACTH secretion, making it a promising tool in preclinical studies of neuroendocrine disorders such as acromegaly and Cushing’s disease. The compound also exhibits antiproliferative and proapoptotic properties, valuable in tumor and endocrine research.

Produced under GMP conditions and with high purity (99.25%), this product supports reliable and reproducible laboratory experiments.

Product Specifications

Mechanism of Action & Research Applications

Pasireotide acetate binds with high affinity to multiple somatostatin receptor subtypes—especially SST5—enabling potent suppression of GH, IGF-I, and ACTH. These effects are critical in models of Cushing’s disease and acromegaly. The compound also demonstrates anti-proliferative and pro-apoptotic effects, making it useful in neuroendocrine tumor research.

Side Effects (Research Context Only)

In experimental settings, Pasireotide acetate may lead to:

• Suppressed hormone secretion

• Elevated glucose levels due to altered pancreatic hormone balance

• Mild gastrointestinal responses such as nausea or gallbladder changes
  These effects are observed in controlled studies and do not apply to clinical use.

Disclaimer

Pasireotide Acetate is designed exclusively for laboratory research use. It is not approved for human, diagnostic, or veterinary use. Handle responsibly, following standard research safety protocols.